title: A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
abstract: Starting from the structure of the novel nonpeptide AT1 receptor antagonist DuP 753 (losartan), a new series of potent antagonists was designed. In these compounds the central imidazole nucleus was replaced by the dihydroimidazol-4-one structure. The most active compounds had a spirocyclopentane or a spirocyclohexane ring in position 5. Like the imidazole series, the best substituents were the linear butyl chain in position 1 and the [2'-(tetrazol-5-yl)biphenylyl]methyl group in position 3. Antagonistic activity was assessed by the ability of the compounds to competitively inhibit [125I]AII binding to the AT1 subtype receptor and to antagonize AII-induced contractions in rabbit aorta rings. The most active compounds had IC50 values in the nanomolar range. In conscious rats, compounds 4 and 21 antagonized the AII pressor response when administered orally. Compound 21 (SR 47436) was the most active; it was recently shown to also be active in cynomolgus monkeys both intravenously and orally. This molecule is now undergoing clinical trials for the treatment of hypertension.
authors.affiliation: Sanofi Recherche, Montpellier, France.
authors.forename: C A
authors.initials: CA
authors.lastname: Bernhart
authors.forename: P M
authors.initials: PM
authors.lastname: Perreaut
authors.forename: B P
authors.initials: BP
authors.lastname: Ferrari
authors.forename: Y A
authors.initials: YA
authors.lastname: Muneaux
authors.forename: J L
authors.initials: JL
authors.lastname: Assens
authors.forename: J
authors.initials: J
authors.lastname: Clément
authors.forename: F
authors.initials: F
authors.lastname: Haudricourt
authors.forename: C F
authors.initials: CF
authors.lastname: Muneaux
authors.forename: J E
authors.initials: JE
authors.lastname: Taillades
authors.forename: M A
authors.initials: MA
authors.lastname: Vignal
mesh_terms: D000804:Angiotensin II / Q000378:metabolism*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001713:Biphenyl Compounds / Q000138:chemical synthesis / Q000494:pharmacology; D005260:Female; D007093:Imidazoles / Q000138:chemical synthesis* / Q000494:pharmacology*; D066298:In Vitro Techniques; D000077405:Irbesartan; D008252:Macaca fascicularis; D008297:Male; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D011945:Receptors, Angiotensin / Q000378:metabolism; D012680:Sensitivity and Specificity; D013329:Structure-Activity Relationship; D013777:Tetrazoles / Q000138:chemical synthesis / Q000494:pharmacology
chemical_list: D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D007093:Imidazoles; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000804:Angiotensin II; D000077405:Irbesartan